Four distinct patterns where doctors saw only one disease
A research team in Lleida has found that type 2 diabetes, long treated as a single condition, can be meaningfully divided into four distinct subtypes at the moment of diagnosis in Mediterranean populations. Studying nearly a thousand patients across Catalonia, scientists identified metabolic profiles that differ from those previously described in Scandinavian cohorts, suggesting that geography and biology together shape how this disease manifests. The discovery invites medicine to move away from uniform treatment protocols and toward a more attentive, individualized understanding of what diabetes actually is in each patient's body.
- Millions of people receive a type 2 diabetes diagnosis each year under a framework that treats the disease as essentially one thing — a simplification this research directly challenges.
- The study of 991 Catalan patients revealed four metabolically distinct subtypes: autoimmune, obesity-driven insulin resistance, insulin deficiency, and age-related forms — each with different risk profiles and likely different responses to treatment.
- Mediterranean patients did not mirror the Scandinavian subtype patterns previously established, raising urgent questions about whether current global clinical guidelines are truly universal.
- Clinicians now face the possibility of reclassifying patients at diagnosis rather than waiting for complications to reveal which form of the disease they actually have.
- The research team is tracking all 991 participants longitudinally to determine whether subtype-informed care genuinely improves outcomes — the answer will determine how far this shift in practice can go.
A research team at the Biomedical Research Institute of Lleida has identified four distinct subtypes of type 2 diabetes that can be recognized at the moment of diagnosis, opening the possibility of personalized treatment from the very beginning of the disease. The finding emerged from the prospective Copernican study, led by Dr. Dídac Mauricio, which recruited 991 newly diagnosed patients across 28 medical centers in Lleida and Barcelona between 2022 and 2026.
While earlier research had mapped diabetes subtypes in Scandinavian populations, the Catalan study revealed meaningful differences when the same approach was applied to Mediterranean patients. Beyond the autoimmune form, the team identified three further subtypes: one combining obesity with insulin resistance, one defined by insufficient insulin production, and one linked to age-related metabolic changes. Each carries a distinct biological signature, suggesting patients may respond differently to the same therapies and face different complication risks.
The practical implications are considerable. Rather than applying a standard protocol to all newly diagnosed patients, clinicians could use subtype classification to guide monitoring and intervention from the outset — matching treatment strategy to the underlying metabolic reality of each individual. Mauricio described the findings as opening the door to a more precise classification that could personalize care from early stages.
The team will continue following all 991 participants over time, tracking subtype progression, treatment response, and the emergence of complications. That longitudinal data will be essential for determining whether earlier, more targeted classification genuinely translates into better health outcomes — and for refining the framework itself as evidence accumulates.
A research team at the Biomedical Research Institute of Lleida has found that doctors can identify distinct subtypes of type 2 diabetes at the moment of diagnosis, opening a path toward more tailored treatment from the earliest stages of the disease. The discovery emerged from a study of nearly a thousand newly diagnosed patients across Catalonia, and it challenges the assumption that type 2 diabetes is a single condition requiring a one-size-fits-all approach.
The research, led by Dr. Dídac Mauricio, the scientific director of the diabetes research area at Ciber, involved 991 people with type 2 diabetes recruited between 2022 and 2026 across 28 medical centers in Lleida and Barcelona as part of the prospective Copernican study. What the team discovered was that the metabolic diversity within type 2 diabetes in Mediterranean populations could be better understood through a framework of four distinct groups—a finding that carries real weight for how clinicians evaluate and classify patients from the moment they receive a diagnosis.
Previous research had identified diabetes subtypes in Scandinavian populations, but this Catalan study revealed important differences when the same analytical approach was applied to Mediterranean patients. Beyond the autoimmune form of diabetes, the researchers identified three additional subtypes: one characterized by obesity paired with insulin resistance, another marked by insufficient insulin production, and a third linked to age-related factors. Each subtype carries its own metabolic signature, suggesting that patients within these groups may respond differently to the same treatments and face different risks for complications.
The implications are substantial. Rather than treating all newly diagnosed type 2 diabetes patients according to a standard protocol, clinicians could potentially use these subtypes to make more informed decisions about monitoring and intervention from the start. A patient with obesity and insulin resistance might benefit from a different therapeutic strategy than one whose primary problem is inadequate insulin production, or one whose condition is driven by age-related metabolic changes. Mauricio emphasized that the findings "open the door to a more precise classification of the disease that could help personalize patient follow-up and treatment from early stages."
The work is far from complete. The research team plans to continue following these 991 participants over time, tracking how each subtype progresses, how patients respond to different treatments, and what complications emerge. This longitudinal data will be crucial for refining the classification system and determining whether identifying subtypes at diagnosis actually leads to better health outcomes. The study represents a shift in how medicine approaches a disease that affects millions—moving away from the assumption that diagnosis alone is enough, toward a more granular understanding of what type 2 diabetes actually is in the bodies of real patients.
Citações Notáveis
The results open the door to a more precise classification of the disease that could help personalize patient follow-up and treatment from early stages.— Dr. Dídac Mauricio, study coordinator
The metabolic heterogeneity of type 2 diabetes in our population could be better represented by a structure of four groups, which has important implications for how we evaluate and classify patients from the moment of diagnosis.— Dr. Dídac Mauricio
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that these subtypes look different in Mediterranean populations than in Scandinavian ones?
Because the disease isn't universal. A patient in Barcelona might have a completely different metabolic problem than a patient in Stockholm, even if they both get the same diagnosis. If you treat them the same way, you're probably failing half of them.
So you're saying the current system is essentially guessing?
Not guessing, exactly. But it's treating the disease as if it's one thing when it's actually four things wearing the same name. A doctor sees "type 2 diabetes" and reaches for the standard playbook. This research says: wait, which of these four patterns are you actually looking at?
How do they know which subtype a patient has?
That's the practical question, isn't it. The study identified them through metabolic markers and clinical characteristics they measured at diagnosis. The next phase is figuring out which tests are simple enough and cheap enough that a regular clinic can use them.
What happens if they don't follow up?
Then this stays a research finding instead of becoming clinical practice. The follow-up data is what proves whether identifying subtypes actually changes outcomes—whether patients do better when you treat them according to their subtype rather than the standard approach.
And if they do better?
Then you've just rewritten how diabetes gets treated in the early stages. That's not small.